Semaglutide, proprietary name OZEMPIC, developed by Novo Nordisk and first approved by USFDA on 05 December 2017 as a GLP-1 receptor agonist and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
GLP-1 therapies, which effectively regulate blood glucose levels and support weight loss, have gained widespread acceptance among healthcare providers (HCPs) and patients
Our dedicated healthcare professionals lead with compassion and evidence-based strategies to empower informed lifestyle modifications and enhance patient confidence
Dehydration can also worsen common tirzepatide side effects like constipation, which may indirectly affect appetite regulation
5 that administrative bonuses were not discussed behind closed doors
These hormones regulate blood sugar levels, control appetite, and promote feelings of fullness, contributing to effective weight loss